David Waterhouse’s insights: First-Line NSCLC Treatment May Include Targeted Agents
David Waterhouse, Chief Innovation Officer at Oncology-Hematology Care, shared the following post on LinkedIn:
“There is no doubt that this class of targeted agents are likely to move into first line NSCLCA treatment. If you are involved in clinical lung cancer research, you want to make sure that such the trial is incorporated into your portfolio. But, it’s not just going to be just for lung cancer. If anyone knows about tissue agnostic drug development, it is Dr. Subbiah.”
This post by David Waterhouse highlights the increasing likelihood of targeted therapies becoming a standard first-line treatment for Non-Small Cell Lung Cancer (NSCLC). Waterhouse emphasizes the importance for those in lung cancer research to include relevant trials in their work. Furthermore, he suggests that the impact of these targeted agents may extend beyond lung cancer, referencing Dr. Subbiah’s expertise in tissue-agnostic drug development.
Quotting Vivek Subbiah’s Post On Linkedin, on Recently Published Article in JCO OP.
“With so many KRAS targeted drugs entering clinical trials pleased to share our editorial in American Society of Clinical Oncology (ASCO) journal JCO OP 👉🏼Ready, Set, Go: Setting Off on the Mission to Target KRAS in Colorectal Cancer”
This post by Vivek Subbiah highlights the increasing number of KRAS-targeted drugs in clinical trials for colorectal cancer, as discussed in their editorial published in the ASCO journal JCO Oncology Practice. The editorial likely emphasizes these therapies’ progress and future potential in treating this challenging disease.
You can read the full Article on JCO OP
Read More on OncoDaily
Advances in KRAS G12C-Mutated NSCLC: Key Insights from ELCC 2025
Glecirasib demonstrates efficacy in KRASG12C-mutated NSCLC – ASCO
10 Most Promising Cancer Drugs Not Yet Approved: Solid Tumors – 2024 edition by OncoDaily
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023